Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Affiliation auteursAffiliation ok
TitreTolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
Type de publicationJournal Article
Year of Publication2020
AuteursRoubaud G., Ozguroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M.P, Procopio G., Feyerabend S., Joung J.Y, Gravis G., Nishimura K., Gedye C., Padua C., Shore N., Thiery-Vuillemin A., Gresty C., Brickel N., Burgents J., Allen A., Fizazi K.
JournalANNALS OF ONCOLOGY
Volume31
PaginationS515-S516
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.08.883